Ross C Donehower MD
Professor of Oncology, Professor of Medicine, Johns Hopkins University School of Medicine; Director, Medical Oncology/Hematogy Fellowship Training Program, Director, Division of Medical Oncology
Join to View Full Profile
10803 Falls RoadPavilion Iii Ste 1500Lutherville, MD 21093
Phone+1 410-583-2970
Fax+1 410-583-2980
Dr. Donehower is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1980
Johns Hopkins UniversityResidency, Internal Medicine, 1974 - 1976
University of Minnesota Medical SchoolClass of 1974
Certifications & Licensure
MD State Medical License 1979 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Excellence in Teaching Award American Society of Clinical Oncology, 2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
Clinical Trials
- Penclomedine in Treating Patients With Advanced Solid Tumors Start of enrollment: 1996 Dec 01
- UCN-01 in Treating Patients With Advanced Cancer Start of enrollment: 1998 Jun 01
- MG98 in Treating Patients With Advanced Solid Tumors Start of enrollment: 1999 Feb 22
Publications & Presentations
PubMed
- 3 citationsNivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.Eric S Christenson, Won Jin Ho, Daniel Shu, Jennifer N Durham, Madelena Brancati
Clinical Cancer Research. 2025-08-01 - 5 citationsRAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.Fanfan Xie, Ding Ding, Cong Lin, Dea Cunningham, Michael Wright
JCO Precision Oncology. 2022-06-01 - 6 citationsTrainee-Led Quality Improvement Project to Improve Fertility Preservation Counseling for Patients With Cancer.Laura A. Sena, Ramy Sedhom, Susan C. Scott, Amanda Kagan, Andrew H. Marple
JCO Oncology Practice. 2021-09-25
Press Mentions
Johns Hopkins University Hematology Oncology FellowshipApril 30th, 2017
Grant Support
- Clinical Oncology Research Career Development ProgramNational Cancer Institute1997–2007
- Phase I Trial/Pharmacokinetis Of Tas 103 Solid In TumorsNational Center For Research Resources2000–2002
- Trial Of Bryostatin 1 Given As Continuous Infusion In Cancer PatientsNational Center For Research Resources1998–2002
- Phase I Dose Escalation, Safety, Tolerability Of Tas 103National Center For Research Resources1997–2002
- Phase I Trials Of Anticancer AgentsNational Cancer Institute1998–2000
Professional Memberships
- Fellow
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/ross-donehower
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
